Similarly, targeting glycosylation regulators, particularly STT3 and B3GNT3, also sensitizes tumors to immunotherapy: upregulated STT3 promotes PD-L1 N-glycosylation and stabilization in EMT + CRC cells, and inhibition of STT3 (e.g., via KYA1797K) reduces glycosylation and enhances CD8+ T cell activity [129]. This evidence concerns the gene CD274 and colorectal carcinoma.